This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Sponsored by Exelixis

About this trial

Last updated 11 years ago

Study ID

XL184-017

Status

Completed

Type

Interventional

Phase

Phase 1

Placebo

No

Accepting

18-75 Years
18 to 80 Years
All
All

Trial Timing

Ended 11 years ago

What is this trial about?

The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects. Another objective is to assess the safety and tolerability of cabozantinib in these adult subjects.

What are the participation requirements?

Yes

Inclusion Criteria

- Body weight must be ≥ 50 kg and < 130 kg with a BMI ≤ 38.0 (kg/m2).

- Must use acceptable form of birth control during the course of the study and for 3 months following the single dose of study drug.

- Female subjects of childbearing potential must have a negative pregnancy test at screening and check-in.

- Negative test for HIV; hepatitis A, B, and C.

- Must have adequate vital sign reads at screening and check-in.

- Must be able to comply with dietary and fluid restrictions required for the study.

No

Exclusion Criteria

- History of medical or surgical conditions that would interfere with GI absorption, distribution, metabolism, or excretion of the study drug.

- Recent clinical evidence of pancreatic injury.

- Recent use of drugs known to significantly inhibit or induce P450 CYP3A4 enzymes.

- Previous diagnosis of malignancy.

- Unwilling to forgo use of any over-the-counter or non-prescription preparations.

Locations

Location

Status